Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.74 |
| ▸ | RIPK1 | Q13546 | 15/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13415432 | 0.91 | PIK3CA (0.77) | PIK3CARIPK1 | |
| SCHEMBL22371004 | 0.88 | RIPK1 (0.66) | PIK3CARIPK1 | |
| SCHEMBL30468332 | 0.88 | RIPK1 (0.66) | PIK3CARIPK1 | |
| SCHEMBL22371025 | 0.87 | RIPK1 (0.66) | PIK3CARIPK1PIK3CDAKT1PIK3CB | |
| SCHEMBL30468347 | 0.87 | RIPK1 (0.66) | PIK3CARIPK1PIK3CDAKT1PIK3CB | |
| SCHEMBL3140684 | 0.87 | PIK3CA (0.74) | PIK3CARIPK1PIK3CDAKT1PIK3CB | |
| SCHEMBL3131524 | 0.86 | PIK3CA (0.66) | PIK3CARIPK1 | |
| SCHEMBL3146333 | 0.86 | PIK3CA (0.66) | PIK3CARIPK1 | |
| SCHEMBL3136501 | 0.85 | PIK3CA (0.72) | PIK3CARIPK1PIK3CDAKT1PIK3CB | |
| SCHEMBL3131527 | 0.85 | PIK3CA (1.00) | PIK3CARIPK1PIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885RIPK1 678/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.